Dextromethorphan-d3 (CRM)
(Synonyms: D-Methorphan-d3, DXN-d3) 目录号 : GC45422A Certified Reference Material
Cas No.:524713-56-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dextromethorphan-d3 (CRM) contains three deuterium atoms at the 17-methyl group. It is intended for use as an internal standard for the quantification of dextromethorphan by GC- or LC-mass spectrometry. Dextromethorphan (DXM) is a dextratrorotatory morphinan with structural similarity to levorphanol, codeine, and morphine. Because of its strong antitussive effects, DXM is widely used as a cough suppressant.1 However, it does not provoke opioid activity as is characteristic of several other morphine derivatives. DXM binds to and inhibits NMDA (IC50 = 0.55 μM) and nicotinic receptors (IC50s = 0.7-3.9 μM) and blocks receptor-gated and voltage-gated calcium channels (IC50 = 60 μM) and voltage-gated sodium channels (IC50 = 78 μM).1,2,3 DXM has been used in multimodal analgesic therapies for acute and neuropathic pain.1,4
References
1. Weinbroum, A.A., Rudick, V., Paret, G., et al. The role of dextromethorphan in pain control. Can.J.Anesth. 47(6), 585-596 (2000).
2. Damaj, M.I., Flood, P., Ho, K.K., et al. Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: In vitro and in vivo selectivity. Journal of Pharmacology and Experimental Therapeutics 312(2), 780-785 (2005).
3. Netzer, R., Pflimlin, P., and Trube, G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. European Journal of Pharmacology 238, 209-216 (1993).
4. Chen, Y.W., Chu, K.S., Lin, C.N., et al. Dextromethorphan or dextrorphan have a local anesthetic effect on infiltrative cutaneous analgesia in rats. Anesthesia and Analgesia 104(5), 1251-1255 (2007).
| Cas No. | 524713-56-2 | SDF | |
| 别名 | D-Methorphan-d3, DXN-d3 | ||
| Canonical SMILES | [H][C@]12CCCC[C@@]1(CC3)C4=CC(OC)=CC=C4C[C@@H]2N3C([2H])([2H])[2H] | ||
| 分子式 | C18H22D3NO | 分子量 | 274.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C; protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6443 mL | 18.2216 mL | 36.4431 mL |
| 5 mM | 0.7289 mL | 3.6443 mL | 7.2886 mL |
| 10 mM | 0.3644 mL | 1.8222 mL | 3.6443 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。